XENE News

This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive. Broader markets continue to rally as the Dow and S&P 500 closed at new record highs and the VIX volatility index slid another 6%. Despite these trends, IPO investors remain discerning: in addition to the postponed offerings, this week's...read more

Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, raised $36 million by offering 4 million shares at $9, below the range of $10 to $12. Xenon Pharmaceuticals plans to list on the NASDAQ under the symbol XENE. Xenon Pharmaceuticals initially filed confidentially on 8/16/2013. Jefferies & Co. and Wells Fargo Securities acted as...read more

Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, relaunched its IPO on Monday, two weeks after initially postponing its deal in. The Burnaby, Canada-based company still plans to raise $44 million by offering 4 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Xenon Pharmaceuticals would command a...read more

Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, postponed its IPO on Friday, citing poor market conditions. The Burnaby, Canada-based company was founded in 1996 and booked $27 million in sales for the 12 months ended June 30, 2014. XENE. Xenon Pharmaceuticals initially filed confidentially on 8/16/2013. Jefferies & Co....read more